Drug Trial Radar · NCT01343823
Evaluation of Ecallantide for Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor Induced Angioedema
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
79
Actual
Start
Jun 1, 2011
Primary completion
Jun 1, 2012
Study completion Jun 1, 2012
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Apr 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A double-blind, randomized, controlled trial comparing the safety and effectiveness of conventional therapy with ecallantide to conventional therapy with placebo.
Conditions
- ACE Inhibitor Induced Angioedema
Interventions
ecallantide 60 mgDrug
Administered as two 3 mL SC injections, each containing 30 mg ecallantide
ecallantide 30 mgDrug
Administered as one 3 mL SC injection containing 30 mg ecallantide
ecallantide 10 mgDrug
Administered as one 3 mL SC injection containing 10 mg ecallantide.
placeboDrug
Administered as two SC 3 mL injections
placebo match for 30 mg ecallantide armDrug
One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
placebo match for 10 mg ecallantide armDrug
One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Efficacy of EcallantideTime frame: 6 hours
Locations
39 sites in 1 country. Site status is shown where the registry gives one.
Er Med, Llc
Montgomery, Alabama
Arrowhead Regional Medical Center
Colton, California
University of California Los Angeles School of Medicine
Los Angeles, California
University of California San Diego Mecial Center
San Diego, California
Christiana Hospital, Department of Emergency Medicine
Newark, Delaware
Washington Hospital Center
Washington D.C., District of Columbia
Tampa General Hospital
Tampa, Florida
Georgia Health Sciences University
Augusta, Georgia
DeKalb Medical
Decatur, Georgia
University Consultants in Allergy and Immunology
Chicago, Illinois
Mercy Hospital and Medical Center
Chicago, Illinois
University of Kansas Medical Center
Kansas City, Kansas
Ochsner Clinic Foundation
New Orleans, Louisiana
Henry Ford Hospital
Detroit, Michigan
Beaumont Hospital, Royal Oak
Royal Oak, Michigan
Beaumont Hospital, Troy
Troy, Michigan
Hennepin County Medical Center
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
Nevada Acess to Research and Education Study
Las Vegas, Nevada
Kings County Hospital Center
Brooklyn, New York
Winthrop University Hospital
Mineola, New York
Staten Island University Hospital
Staten Island, New York
East Carolina University
Greenville, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina
The MetroHealth System
Cleveland, Ohio
University Hospital East
Columbus, Ohio
The Ohio State University Medical Center
Columbus, Ohio
Thomas Jefferson University
Philadelphia, Pennsylvania
Albert Einstein Medical Center
Philadelphia, Pennsylvania
Allegheny General Hospital
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
University Medical Center Brackenridge
Austin, Texas
St Joseph Regional Health Center
Bryan, Texas
UT Southwestern Medical Center at Dallas
Dallas, Texas
Emergency Medicine Residency Program
Fort Worth, Texas
301 University Blvd.
Galveston, Texas
Baylor College of Medicine
Houston, Texas
University of Virginia Health System
Charlottesville, Virginia
Sentara Norfolk General Hospital
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.